The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Real-world outcomes of Asian patients with advanced BRAF-mutant melanoma treated with first-line BRAF/MEK inhibitors, anti-PD-1 monotherapy, or combination of nivolumab plus ipilimumab: A multicenter retrospective study in Japan (B-CHECK-RWD study).
 
Kenjiro Namikawa
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
Consulting or Advisory Role - Novartis
Research Funding - Ono Pharmaceutical (Inst)
 
Takamichi Ito
No Relationships to Disclose
 
Shusuke Yoshikawa
No Relationships to Disclose
 
Koji Yoshino
No Relationships to Disclose
 
Yukiko Kiniwa
No Relationships to Disclose
 
Tatsuya Takenouchi
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
 
Hiroshi Kato
Consulting or Advisory Role - MTG Therapeutics
Speakers' Bureau - AbbVie; Aceutical; Maruho; MSD; Novartis; Ono Pharmaceutical
Research Funding - AbbVie; Eisai; Maruho; Mitsubishi Tanabe Pharma; MTG Therapeutics
 
Satoru Mizuhashi
No Relationships to Disclose
 
Yosuke Yamamoto
No Relationships to Disclose
 
Yasuhiro Fujisawa
Consulting or Advisory Role - Lilly; Novartis
Speakers' Bureau - Novartis; Ono pharmaceutical
Research Funding - Eisai; Ono pharmaceutical
 
Osamu Yamasaki
No Relationships to Disclose
 
Yasuhiro Nakamura
Honoraria - Bristol-Myers Squibb Japan; Kyowa Kirin International; Maruho; Mitsubishi Tanabe Pharma; MSD Oncology; Novartis Pharmaceuticals UK Ltd.; Ono Pharmaceutical; Taiho Pharmaceutical; Taisho Toyama Pharma
Consulting or Advisory Role - Novartis Pharmaceuticals UK Ltd.
Research Funding - Kaken Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pola Pharma (Inst); Torii Pharmaceutical (Inst)
 
Jun Asai
No Relationships to Disclose
 
Takeo Maekawa
No Relationships to Disclose
 
Shigeto Matsushita
No Relationships to Disclose
 
Eiji Nakano
No Relationships to Disclose
 
Kohei Oashi
No Relationships to Disclose
 
Hisashi Uhara
No Relationships to Disclose
 
Takuya Miyagawa
No Relationships to Disclose
 
Naoya Yamazaki
Consulting or Advisory Role - Chugai Pharma; MSD; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Novartis; Ono Pharmaceutical
Research Funding - Astellas Amgen BioPharama (Inst); Bristol-Myers Squibb Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Takara Bio (Inst)